Contact information
Research groups
Colleges
Antony Psarras
MD MSc PhD MRCP
NIHR Academic Clinical Lecturer in Rheumatology
- Academic Clinical Lecturer
- Honorary Specialty Registrar in Rheumatology, Nuffield Orthopaedic Centre
I am an Academic Clinical Lecturer and an Honorary Specialty Registrar in Rheumatology at the University of Oxford and the Nuffield Orthopaedic Centre. I qualified in Medicine from Aristotle University of Thessaloniki (Greece) in 2014 and I then followed postgraduate studies (MSc) in Immunology at Imperial College London. I successfully completed a PhD in 2018 investigating type I interferon regulation in the pathogenesis of systemic lupus erythematosus, supervised by Dr E. Vital and Prof P Emery at University of Leeds along with Prof G. Tsokos at Harvard Medical School.
After completing my Internal Medicine Training at King's College Hospital in London in 2022, I moved to Oxford to join Alex Clarke's group in the Kennedy Institute of Rheumatology, supported by the NIHR Academic Clinical Lectureship scheme. My main research interest lies in immune regulation of rheumatic diseases, currently focusing on immune cell metabolism and its role in autoimmunity. I am also a Teaching Associate at Green Templeton College, University of Oxford.
Key publications
-
Functionally impaired plasmacytoid dendritic cells and non-haematopoietic sources of type I interferon characterize human autoimmunity.
Journal article
Psarras A. et al, (2020), Nat commun, 11
-
Type I interferon–mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy
Journal article
Psarras A. et al, (2017), Rheumatology, kew431 - kew431
-
Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status
Journal article
Md Yusof MY. et al, (2018), Annals of the rheumatic diseases, 77, 1432 - 1439
-
Emerging concepts of type I interferons in SLE pathogenesis and therapy
Journal article
Psarras A. et al, (2022), Nature reviews rheumatology
Recent publications
-
Type 1 interferons: A target for immune-mediated inflammatory diseases (IMIDs).
Journal article
Mathian A. et al, (2023), Joint bone spine, 91
-
A cellular overview of immunometabolism in systemic lupus erythematosus
Journal article
Psarras A. and Clarke A., (2023), Oxford open immunology, 4
-
Management and treatment of children, young people and adults with systemic lupus erythematosus: British Society for Rheumatology guideline scope.
Journal article
Md Yusof MY. et al, (2023), Rheumatol adv pract, 7
-
Anti-BDCA2 Antibody for Cutaneous Lupus Erythematosus.
Journal article
Psarras A. and Vital EM., (2022), N engl j med, 387, 1528 - 1529
-
Emerging concepts of type I interferons in SLE pathogenesis and therapy
Journal article
Psarras A. et al, (2022), Nature reviews rheumatology
-
Keratinocytes: From passive targets to active mediators of systemic autoimmunity
Journal article
Psarras A. and Vital EM., (2022), Science translational medicine, 14